Drugmakers say HHS’ 340B pilot is limited as they fight for their own rebate modelsnews2025-11-17T21:00:33+00:00November 17th, 2025|Endpoints News|
Zymeworks and Jazz tout HER2 bispecific success in first Phase 3 readoutnews2025-11-17T20:44:06+00:00November 17th, 2025|Endpoints News|
New US trade deal caps Switzerland, Liechtenstein pharma tariffs at 15%news2025-11-17T19:14:06+00:00November 17th, 2025|Endpoints News|
Novo Nordisk lowers self-pay prices for weight loss drugs ahead of Lilly, TrumpRxnews2025-11-17T18:22:42+00:00November 17th, 2025|Endpoints News|
Scholar Rock plans to launch spinal muscular atrophy drug next yearnews2025-11-17T17:48:23+00:00November 17th, 2025|Endpoints News|
Jeffrey Bluestone hands Sonoma CEO post to Stephen Dillynews2025-11-17T16:26:56+00:00November 17th, 2025|Endpoints News|
How the Lilly-Adverum deal came together; Captain T Cell reels in €20Mnews2025-11-17T16:10:06+00:00November 17th, 2025|Endpoints News|
Terray Therapeutics unveils AI platform EMMI, selection modelnews2025-11-17T16:00:31+00:00November 17th, 2025|Endpoints News|
Merck is still hunting for deals after two major bolt-on acquisitions this yearnews2025-11-17T15:58:32+00:00November 17th, 2025|Endpoints News|
J&J to buy Halda for $3.05B, adding startup’s RIPTAC cancer drugnews2025-11-17T14:27:30+00:00November 17th, 2025|Endpoints News|
